BCRX — BioCryst Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.05bn
- $2.52bn
- $874.84m
U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx SE, Cardinal Health Inc
BioCryst Pharmaceuticals down after quarterly revenue miss
BioCryst Pharma Q3 operating profit up, raises FY ORLADEYO sales guidance
U.S. RESEARCH ROUNDUP-BlackRock, EQT, Ovintiv
Astria surges on BioCryst's $700 mln buyout deal
Deals of the day-Mergers and acquisitions
Astria surges on BioCryst's $700 mln buyout deal
BioCryst to buy Astria Therapeutics in $700 million deal (updated)
BioCryst to buy Astria Therapeutics in $700 million deal
Brief: BioCryst To Acquire Astria Therapeutics, Strengthening Presence In Hae, Transforming Growth Profile
U.S. RESEARCH ROUNDUP- AGCO, Caterpillar, United Rentals
Brief: Biocryst Completes Sale Of European Orladeyo® (Berotralstat) Business
Brief: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Tyson Foods, BioNTech, gold miners
U.S. STOCKS ON THE MOVE-Tyson Foods, BioNTech, Gold miners
BioCryst Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Axsome Therapeutics, Wayfair, IDEXX Laboratories
BioCryst Pharma rises after bigger quarterly sales
BioCryst posts bigger Q2 revenue, profit on strong demand for skin disease drug ORLADEYO